SPPI Share Price

Open 19.37 Change Price %
High 19.94 1 Day 0.22 1.14
Low 19.37 1 Week 0.00 0.00
Close 19.59 1 Month 6.23 46.63
Volume 1351331 1 Year 15.09 335.33
52 Week High 21.95
52 Week Low 3.85
SPPI Important Levels
Resistance 2 20.12
Resistance 1 19.90
Pivot 19.63
Support 1 19.28
Support 2 19.06
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)

SPPI Technical Analysis 5
As on 31st Oct 2017 SPPI Share Price closed @ 19.59 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.69 & Strong Buy for SHORT-TERM with Stoploss of 12.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
SPPI Target for December
1st Target up-side 24.36
2nd Target up-side 27.71
3rd Target up-side 31.06
1st Target down-side 14.82
2nd Target down-side 11.47
3rd Target down-side 8.12
SPPI Other Details
Segment EQ
Market Capital 683767552.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SPPI Address
SPPI
N/A
SPPI Latest News
Interactive Technical Analysis Chart Spectrum Pharmaceuticals, Inc. ( SPPI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Spectrum Pharmaceuticals, Inc.
SPPI Business Profile
Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.